Inhaled biologics are being evaluated as an alternative to injections for treating rare and serious diseases. Experts touch on several challenges including making stable and safe formulations of inhaled biologics.
When designing drug-delivery devices, the patient must be at the centre of the development process. Nélio Drumond of Takeda Pharmaceuticals discusses how this patient-centric approach allows the design to maximise efficiency and efficacy.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.